Need help? +44 (0) 7457 418426

MEDICINE DETAILS

Jyseleca

Active ingredient: Filgotinib

Jyseleca is recorded in this directory with the active ingredient Filgotinib. This page brings together catalogue strength, dosage-form and pack records so they can be checked against a prescription.

NEXT STEP

Choose the strength and pack

✓ If you are unsure, choose “I do not know”.

These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.

ABOUT THIS MEDICINE

What is Jyseleca used for?

Jyseleca (filgotinib) is a Janus kinase 1 (JAK1) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

It is indicated for patients who do not respond or are intolerant to other anti-rheumatic medicines.

It can be used on its own (monotherapy) or together with another anti-rheumatic medicine, methotrexate (MTX).

Jyseleca (filgotinib) is available as 200 mg tablets.

This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.

RECORDED PRODUCT PROFILE

Jyseleca identity, dosage form and pack information.

The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.

Brand recordJyseleca
Active ingredientFilgotinib
Dosage formfilm-coated tablets
Recorded options4
Directory areaRheumatology
Catalogue synchronised

Recorded strength and pack options

Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.

  1. 100 mg · 30 tablets Catalogue organisation: Alfasigma GmbH
  2. 100 mg film-coated tablets · 90 tablets Catalogue organisation: Abacus Medicine A/S
  3. 200 mg · 30 tablets Catalogue organisation: Alfasigma GmbH
  4. 200 mg film-coated tablets · 90 tablets Catalogue organisation: Abacus Medicine A/S

OFFICIAL SOURCES

Check the Jyseleca record at an official source.

Search for “Jyseleca” or “Filgotinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.

SERVICE BOUNDARY

Information checking and independent enquiry support for Jyseleca.

OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.

Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.

CLEAR ANSWERS

Frequently asked questions about Jyseleca

01What is Jyseleca?

This directory record associates the brand name Jyseleca with the active ingredient Filgotinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.

02Which Jyseleca strengths and packs are recorded?

The catalogue currently shows: 100 mg · 30 tablets; 100 mg film-coated tablets · 90 tablets; 200 mg · 30 tablets; 200 mg film-coated tablets · 90 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.

03Who manufactures Jyseleca?

Catalogue records currently name: Alfasigma GmbH, Abacus Medicine A/S. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.

04Do the listed options confirm stock or access?

No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.

05What affects a possible estimated medicine cost for Jyseleca?

A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Jyseleca, payment request, stock guarantee or binding offer.

06Can I buy Jyseleca from this website?

No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.